written on 02.06.2014
Tags:
,

Teva, Mylan begin their generic takedown of Pfizer's $2.9B-a-year Celebrex

TAGS: ,

In March, a U.S. court struck down a key patent for Pfizer's Celebrex, suddenly opening the drug up to copycat rivals. Now, that competition has arrived as the FDA gave the green light to Celebrex copies from Teva Pharmaceutical and Mylan.

Latest Report